Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare Inc. (PBH) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
pbh · pe ratio · data through Mar 31, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Prestige Consumer Healthcare Inc. (PBH) measures how much investors pay for each dollar of the company's trailing earnings. PBH's current PE ratio of 11.89x is calculated by dividing its stock price of $48.98 by its TTM earnings per share of $4.01. −24.2% discount vs 5Y avg 15.7x
Source: FMP · /ratios-ttm · /analyst-estimates · 2026-03-31
PE Ratio History
2007 – 2026 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 17 fiscal years · Front-end computedMinQ1 · 25%17.0x
MedianQ3 · 75%42.4x
Max
At 11.89x, PBH's current P/E is lower than in 6% of its annual fiscal year readings over the past 17 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Distribution · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Prestige Consumer Healthcare Inc.You PBH | $2.3B | 11.89x | -99.3% | $4.01 |
 Alphatec Holdings, Inc. ATEC | $1.2B | N/A | — | -$0.96 |
 Concentra Group Holdings Parent, Inc. CON | $3.3B | 14.42x | -99.1% | $1.36 |
 Catalyst Pharmaceuticals, Inc. CPRX | $3.8B | 13.32x | -99.2% | $1.75 |
 Heartflow, Inc. Common Stock HTFL | $2.5B | N/A | — | -$0.32 |
 ICU Medical, Inc. ICUI | $3.4B | 4802.44x | +198.3% | $0.03 |
 Disc Medicine, Inc. IRON | $2.5B | N/A | — | -$6.01 |
Industry Average 3 peers with valid PE | — | 1610.06x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2026-03-31Latest FY2026 | 15.09x | $3.93 | -24.2% | |
2025-03-31 FY2025 | 19.91x | $4.32 | +16.9% | |
2024-03-31 FY2024 | 17.04x | $4.21 | — | |
2023-03-31 FY2023 | — | $-1.65 | — | |
2022-03-31 FY2022 | 12.96x | $4.09 | -3.6% | |
2021-03-31 FY2021 | 13.44x | $3.28 | +2.8% | |
2020-03-31 FY2020 | 13.08x | $2.81 | — | |
2019-03-31 FY2019 | — | $-0.69 | — | |
2018-03-31 FY2018 | 5.27x | $6.40 | -87.6% | |
2017-03-31 FY2017 | 42.41x | $1.31 | +50.5% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Prestige Consumer Healthcare Inc. (PBH) measures how much investors pay for each dollar of the company's trailing earnings. PBH's current PE ratio of 11.89x is calculated by dividing its stock price of $48.98 by its TTM earnings per share of $4.01.
Frequently asked questions
PBH pe ratio · 6 questionsPBH's current PE ratio is 11.89x as of 2026-06-09, based on a stock price of $48.98 and TTM EPS of $4.01. Data sourced from Financial Modeling Prep via PBH's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Prestige Consumer Healthcare Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09